decisionhealth Newsletters, Part B News - 2003 Issue 1 (January)
PE fix to come before new rule is used to slash drug payments, CMS says
Subscribe or sign in to view the full article.
Article Overview
This news article covers a CMS announcement about Medicare drug payment policy, with emphasis on practice expense adjustments, the inherent reasonableness review process, and concerns raised by oncology providers and other stakeholders. It discusses how the policy fits alongside other drug reimbursement changes, the role of federal rulemaking, and the broader debate over payment adequacy for physician-administered drugs and related services. The piece is relevant to coders, billing staff, oncology practices, and reimbursement professionals following Medicare Part B drug payment policy.
Why This Topic Matters
Changes to Medicare drug reimbursement can affect office-based oncology billing, practice expense payment levels, and future Medicare payment policy. Readers tracking Part B reimbursement and CMS rulemaking need to understand the policy context and stakeholder concerns discussed in the article.
What You Will Learn
- How CMS is approaching practice expense adjustments before drug payment revisions
- What the article says about Medicare reimbursement concerns in oncology practices
- How the policy is connected to broader drug payment and equipment reimbursement discussions
- Which stakeholder groups are involved in the debate over Medicare drug payment changes
Who Should Read This
- Medical coders
- Billing specialists
- Revenue cycle staff
- Oncology practice administrators
- Compliance professionals
- Medicare reimbursement analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com